Asthma Clinical Trial
— EmBRAiZOfficial title:
Implementation of Evidence-based Breathing Retraining for Patients With Asthma in Region Zealand, Denmark
This study aims to implement the evidence-based intervention breathing retraining into clinical care of patients with symptomatic asthma irrespective of asthma severity or comorbidities, and in a diverse multicentre setting to evaluate implementation outcomes. This will meet patients' needs and improve health and life situation in patients with uncontrolled asthma. Further, the study will evaluate implementation outcomes.
| Status | Recruiting |
| Enrollment | 300 |
| Est. completion date | December 31, 2025 |
| Est. primary completion date | December 31, 2024 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: - Doctor diagnosed asthma; - Incompletely controlled asthma or worse: Asthma Control Questionnaire (ACQ5) score =0.8; - Residence (or asthma treatment program) in Region Zealand, Denmark; - Able to read and understand Danish or available assistance to help understand information material, intervention content and respond to questionnaires. Exclusion Criteria: - Unwilling to participate; - Unable to participate in the intervention due to physical or mental condition. |
| Country | Name | City | State |
|---|---|---|---|
| Denmark | Naestved Hospital | Naestved | Region Zealand |
| Lead Sponsor | Collaborator |
|---|---|
| Naestved Hospital |
Denmark,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Other | Ashma severity by Global Initiative for Asthma (GINA) treatment steps | Patient-related outcome. Asthma severity assessed by pharmacotherapy level, calculated into GINA treatment steps 1-5 (1 = mild asthma, 5 = severe asthma), using a questionnaire completed by the physiotherapist during an interview with the patient. | Change from baseline to 12 month | |
| Other | Adverse events (Safety) | Patient-related outcome; number, % caused discontinuation. | Post-intervention (3-month) | |
| Other | Asthma Control Questionnaire, ACQ5 | Patient-related outcome: ACQ5 i.e. item 1-5 of the ACQ. Mean of asthma symptom level questionnaire; 7-point Likert scales from 0-6, 0 = better outcome, 6 = worse outcome. | Change from baseline to 12 month | |
| Other | Number of online sessions delivered | Number, % of total sessions. | Post-intervention (3-month) | |
| Primary | Adoption of intervention (Uptake) | Organization-related (Pulmonologists, general practioners, physiotherapists) outcome: Proportion of general practices and of hospitals that will adopt BR. | Through study completion, an average of 1 year | |
| Primary | Implementation of intervention (Fidelity) | Organization-related (physiotherapists) outcome:
% of contents delivered as planned assessed by a checklist of key aspects in the breathing retraining-intervention. |
Through study completion, an average of 1 year | |
| Primary | Feasibility of online sessions in Hybrid delivery mode of BR (H-BR) (Acceptability) | Patient- and Organization-related (physiotherapists) outcome: assessed by a semi-structured interview. | Through study completion, an average of 1 year | |
| Primary | Effectiveness: MiniAsthma Quality of Life Questionnaire, MiniAQLQ | Patient-related outcome, disease specific quality of life questionnaire. 7-point Likert scales from 1-7, 1 = worse outcome, 7 = better outcome.
Success rates of improvements minus deteriorations of individual effects, measured at 12 month follow up. |
Through study completion, an average of 1 year | |
| Secondary | MiniAsthma Quality of Life Questionnaire, MiniAQLQ | Patient-related outcome: Mean of disease specific quality of life questionnaire. 7-point Likert scales from 1-7, 1 = worse outcome, 7 = better outcome. | Change from baseline to 12 months | |
| Secondary | Breathing pattern observation | Patient-related outcome. Pre-defined key aspects of the breathing pattern assessed qualitatively observation by the physiotherapist. | Change from baseline to 12 month | |
| Secondary | Objective physical activity level | Patient-related outcome. Objectively measured physical activity and inactivity using combined wearable thigh and wrist accelerometers, worn for seven consecutive days. | Change from baseline to 12 month | |
| Secondary | Objective steps per day (average) | Patient-related outcome. Objectively measured steps per day using combined wearable thigh and wrist accelerometers, worn for seven consecutive days. | Change from baseline to 12 month |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
| Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
| Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
| Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
| Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
| Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
| Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
| Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
| Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
| Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
| Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
| Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
| Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
| Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
| Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
| Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
| Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
| Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
| Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
| Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|